Success Metrics

Active Trials
2(67%)

Phase Distribution

Ph phase_1
1
33%
Ph early_phase_1
2
67%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
2(66.7%)
Phase 1Safety & dosage
1(33.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Not yet recruiting1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 12 (66.7%)
Phase 11 (33.3%)

Trials by Status

not_yet_recruiting133%
active_not_recruiting133%
recruiting133%

Recent Activity

2 active trials
Showing 3 of 3
recruitingearly_phase_1

Window of Opportunity Study of DSP-0390 in Gliomas

NCT06636162
not_yet_recruitingphase_1

DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer

NCT07545954
active_not_recruitingearly_phase_1

Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

NCT05023551

Clinical Trials (3)

Showing 3 of 3 trials
NCT06636162Early Phase 1

Window of Opportunity Study of DSP-0390 in Gliomas

Recruiting
NCT07545954Phase 1

DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer

Not Yet Recruiting
NCT05023551Early Phase 1

Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

Active Not Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3